Mirtabene (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, increasing norepinephrine release, and antagonizes postsynaptic 5‑HT2 and 5‑HT3 receptors. This dual action boosts overall serotonergic activity while reducing certain serotonin‑related side effects, contributing to its antidepressant effect.

The appropriate dose of Mirtabene is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for mirtazapine in pregnancy and lactation are limited. The prescriber must weigh potential benefits against possible risks to the fetus or infant before deciding to use Mirtabene during pregnancy or while breastfeeding.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtabene (mirtazapine) belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. This profile often results in strong sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Mirtabene should be stored at ambient temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Mirtabene is taken orally, usually once daily in the evening with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush or chew unless specifically instructed.

Serious risks include agranulocytosis or severe neutropenia, serotonin syndrome when combined with other serotonergic drugs, and the emergence or worsening of suicidal thoughts, especially during the initial treatment period. Prompt medical attention is required if any of these occur.

Mirtabene is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or those who have shown hypersensitivity to mirtazapine. Caution is advised for individuals with severe hepatic impairment, uncontrolled hypertension, or a history of bipolar disorder where antidepressant-induced mania is a concern.